867 — China Medical System Holdings Share News
0.000.00%
Last trade - 00:00- HK$24.82bn
- HK$19.26bn
- CNY8.21bn
Brief: China Medical System Holdings Says Dermavon Receives NMPA Approval For Lumirix NDA For Atopic Dermatitis
China Medical System climbs most in six weeks on higher profit, dividend
China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
AI shortens drug discovery to around 1 year in China, Insilico CEO says
Brief: China Medical System Says Nmpa Approves Clinical Trials Of CMS-D017
Taiwan's Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine (updated)
China Medical System to pay Insilico up to $177 million for nervous system work (updated)
China Medical System to pay Insilico up to about $177 million for central nervous system work
Brief: China Medical System Says NPMA Approved CMS-D001 Granted Drug Clinical Trial
Brief: China Medical System Posts FY Turnover Up 9.9% To RMB8,212.1 Million
Brief: China Medical System Posts Profit For Year Rmb1,443.3 Million
Brief: China Medical System Says New Drug For Renal Anaemia Desidustat Tablets Approved For Marketing By China NMPA
Brief: China Medical System Holdings Says CMS-D008 Receives Drug Clinical Trial Approval From China's NMPA
Brief: CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted
Brief: China Medical System Gets Acceptance From China's NMPA For New Drug Application Of Ruxolitinib Phosphate Cream For Treatment Of Atopic Dermatitis
Brief: China Medical System Signs Exclusive Distribution Agreement For Lidoderm Lidocaine Cataplasms
InSilico hits fresh high on partnership deal with China Medical
Brief: China Medical System Holdings Says CMS-D017 Capsules Receive Clinical Trial Approval From Nmpa
Brief: China Medical System Says CMS-D017 Capsules Obtain Drug Clinical Trial Approval